Posted By: Kylee Spencer, PhD, Assistant Editor, AJHG KS: What motivated you to start working on this project? SG: Tumor Mutational Burden (TMB) is one of a few FDA approved biomarkers for immunotherapy in solid tumors but the mechanisms for why certain tumors are TMB-high and why certain TMB-high tumors still do not respond to... Read More
Posted By: Kylee Spencer, PhD, Assistant Editor, AJHG KS: What motivated you to start working on this project? DF: I initially trained as a chemist, so I’m surprised to have written this paper about variants of uncertain significance. I moved from chemistry to genomics because it was, and still is, a hotbed of technological development.... Read More
Posted By: HGG Advances HGGA: What motivated you to start working on this project? CS: In order to move from genome-wide associated loci toward potentially effective clinical and therapeutic targets, we need to identify which target/effector gene(s) the associate variants are being modulated. There are multiple methods that currently exist that can be used to... Read More
By Brendan Lee, MD, PhD I’ve been a member of ASHG for over 30 years. And I suspect, like many of you, my first interaction with the Society was as a trainee presenting posters at the annual meeting. Throughout the years, I participated in a number of activities first as a mentee and then as... Read More
Learn How ASHG Board of Director Candidates are Identified and Elected and Consider if Board Service is in Your Future. ASHG is committed to engaging members in the life of the Society. Elections provide a valuable opportunity to select leaders who can effectively represent both the Society and the scientific community. Acting on behalf of... Read More
ASHG uses cookies to provide you with a secure and custom web experience. Privacy Policy